Telix Pharmaceuticals Limited Investor Relations Material
Latest events
H2 2023
Telix Pharmaceuticals Limited
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Telix Pharmaceuticals Limited
Access all reports
Telix Pharmaceuticals Limited is a global biopharmaceutical company at the commercial stage, primarily engaged in developing diagnostic and therapeutic products using targeted radiation for cancer and rare diseases. The company is pioneering in the field of radiopharmaceuticals, aiming to advance precision medicine through its innovative approach. Telix's product development focuses on molecularly targeted radiation (MTR) products that seek to improve patient outcomes by precisely targeting diseased cells, thereby minimizing the impact on healthy tissues. Its research pipeline includes a range of diagnostic and therapeutic agents for conditions such as prostate cancer, kidney cancer, glioblastoma (brain cancer), and hematologic cancers, as well as bone marrow conditioning for rare diseases. TThe company is headquartered in North Melbourne, Australia, and its shares are listed on the ASX.
Key slides for Telix Pharmaceuticals Limited
H2 2023
Telix Pharmaceuticals Limited
H2 2023
Telix Pharmaceuticals Limited
Latest articles
The World of Luxury: Creating and Selling Desirability
Dive into the enchanting world of high-end allure, where the art of exclusivity shapes desire, turning luxury into an emblem of unique prestige.
6 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Ticker symbol
Country
🇦🇺 Australia